The ARSA knockout A-549 polyclonal cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma epithelial cell line. This product features targeted disruption of the ARSA gene, which encodes arylsulfatase A, a lysosomal enzyme critical for sulfatide catabolism. The polyclonal format provides a heterogeneous population of edited cells, enabling robust loss-of-function studies without clonal selection artifacts. These cells serve as a reliable model for investigating ARSA deficiency and associated lysosomal storage disorders.
The parental A-549 cell line originates from human lung adenocarcinoma tissue and exhibits adherent epithelial morphology. Widely used as a model for alveolar type II pneumocytes, A-549 cells express wild-type p53 and retain key characteristics of pulmonary epithelial cells. This background provides a physiologically relevant system for examining sulfatide metabolism, lysosomal function, and disease-associated cellular phenotypes in lung-derived cells.
ARSA hydrolyzes sulfate esters of sulfatide to generate galactosylceramide, an essential step in lysosomal sphingolipid degradation. The enzyme is transcriptionally regulated by upstream factors such as TFEB and SP1, and its activity depends on the cofactor saposin B (SAP-B) for substrate presentation. Disruption of ARSA function leads to sulfatide accumulation, which acts downstream to perturb lysosomal membrane stability, activate inflammatory mediators, and trigger apoptotic signals. Representative pathway components include PSAP, cerebroside sulfatide, and other lysosomal hydrolases that coordinate sphingolipid homeostasis.
In A-549 cells, ARSA knockout replicates key aspects of metachromatic leukodystrophy, a severe lysosomal storage disorder characterized by sulfatide accumulation and progressive neurodegeneration. Although A-549 cells are non-neuronal, they offer a convenient model to study sulfatide-induced lysosomal stress in epithelial cells, which may contribute to pulmonary manifestations in some lysosomal disorders. The knockout model also enables investigation of cross-talk between sphingolipid metabolism and lung cancer cell biology, given the A-549 origin.
These polyclonal ARSA knockout cells are suitable for screening pharmacological chaperones, enzyme replacement therapies, or small molecules targeting sulfatide reduction. Typical assays include ARSA enzyme activity measurement, western blotting for protein expression, LC-MS-based sulfatide quantification, and immunofluorescence analysis of lysosomal markers such as LAMP1. Functional studies can assess cell viability, apoptosis, and migration under sulfatide accumulation conditions, providing insights into disease mechanisms and therapeutic interventions. For technical inquiries or to discuss custom requirements, please contact Ascent Research.
